Three contracting organizations based near the Ohio state capital are beginning the year with multi-million dollar deals.
Technology company Battelle, contract researcher AmplifyBio, and CDMO Andelyn Biosciences have been awarded an eight-year, $149 million, unlimited delivery, unlimited volume contract from the National Institute of Neurological Disorders and Stroke, Supporting advances in the treatment of neurological conditions.
A Battelle spokesperson said: endpoint news I emailed that the company’s role will include program management and technical leadership in assay development.
AmplifyBio’s role will focus on preclinical research, including design and support for neurological safety and efficacy. AmplifyBio spokesperson said the work includes support for novel and specialized routes of administration. in vitro Analyzes of efficacy and neurobehavioral studies. Andelyn is the manufacturing partner for this deal.
The agreement itself covers eight therapeutic types, including oligonucleotides, viral vectors, purified proteins, peptides, ADCs, cell therapies, genome-editing modalities and nanoparticle-based formulations, according to an AmplifyBio spokesperson. However, a Battelle spokesperson said, “We’ll have to wait and see what task orders are issued.”
The transaction is also a strong step forward for all parties involved.
“This will allow us to apply our expertise in neurospace to evaluate the safety and efficacy of these drugs and support the extensive characterization of these drugs to provide greater insight into their successful commercialization.” The deal also allows us to continue our strong partnership with Battelle and initiate a new partnership with Andelyn Bioscience, highlighting the strength of our Central Ohio hub for advancing new medicines. will be available,” said an AmplifyBio spokesperson.
AmplifyBio, which spun out of Battelle in 2021, expanded rapidly in the Columbus, Ohio area last year. In May, CRO received about $150 million to build a new 350,000-square-foot facility, on top of which he raised nearly $200 million.
Also, following the layoff of PACT Pharma last year, AmplifyBio also acquired space on the west side, specifically a 46,280-square-foot lab in South San Francisco, California, where about 40 employees will work on PACT’s cells and genes. Specializing in therapeutic development.
